673487-34-8

Basic information

• Product Name: 5-FLUORO-2-(TRICHLOROMETHYL)-1H-BENZIMIDAZOLE
• Synonyms: 5-FLUORO-2-(TRICHLOROMETHYL)-1H-BENZIMIDAZOLE;1H-BenziMidazole, 6-fluoro-2-(trichloroMethyl)-;6-fluoro-2-(trichloromethyl)-1H-Benzimidazole
• CAS NO: 673487-34-8
• Molecular Formula: C8H4Cl3FN2
• Molecular Weight: 253.49
• Mol File: 673487-34-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-FLUORO-2-(TRICHLOROMETHYL)-1H-BENZIMIDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-FLUORO-2-(TRICHLOROMETHYL)-1H-BENZIMIDAZOLE(673487-34-8)
• EPA Substance Registry System: 5-FLUORO-2-(TRICHLOROMETHYL)-1H-BENZIMIDAZOLE(673487-34-8)

Safety Data

• Hazardous Substances Data: 673487-34-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-FLUORO-2-(TRICHLOROMETHYL)-1H-BENZIMIDAZOLE is used as a potential therapeutic agent for its potential anticancer and antiviral activities. The presence of the trichloromethyl group enhances its bioavailability and uptake in biological systems, making it a promising candidate for further research and development in the pharmaceutical field.
Used in Anticancer Applications:
In the field of oncology, 5-FLUORO-2-(TRICHLOROMETHYL)-1H-BENZIMIDAZOLE is used as a potential anticancer agent. Its specific mechanisms of action and therapeutic potential are still under investigation, but its unique chemical structure suggests it may have the ability to target and inhibit cancer cell growth and proliferation.
Used in Antiviral Applications:
5-FLUORO-2-(TRICHLOROMETHYL)-1H-BENZIMIDAZOLE is also being studied for its potential antiviral properties. The trichloromethyl group may play a role in its interaction with viral components, potentially inhibiting viral replication or assembly. Further research is necessary to explore its full antiviral potential and to identify specific viruses it may be effective against.

Upstream product

• 367-31-7 4-fluoro-1,2-phenylenediamine 
• 2533-69-9 methyl 2,2,2-trichloroacetimidate 
• 2369-11-1 5-fluoro-2-nitroaniline 

Downstream Products

• 29958-83-6 2-Cyano-5-fluor-benzimidazol 
• 29958-83-6 6-fluoro-1H-benzimidazole-2-carbonitrile 
• 876710-76-8 5-fluoro-1H-benzimidazole-2-carboxylic acid 

Relevant articles and documents

AZA-HETEROARYL COMPOUNDS AS PI3K-GAMMA INHIBITORS

The present invention provides aza-heteroaryl derivatives of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A, W, R4, R5, and R6 are defined herein, that inhibit the activity of phosphoinositide 3-kinases-gamma (PI3Kγ) and are useful in the treatment of diseases related to the activity of PI3Kγ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

Synthesis of novel histamine H4 receptor antagonists

This letter describes the discovery and synthesis of a series of octahydropyrrolo[3,4-c]pyrrole based selective histamine hH4 receptor antagonists. The amidine compound 20 was found to be a potent and selective histamine H4 receptor antagonist with moderate clearance and a high volume of distribution.

CARBAMATE COMPOUND OR SALT THEREOF

[Problems] A compound useful as an active ingredient for a pharmaceutical composition for treating FAAH-related diseases is provided. [Means for Solution] The present inventors have made extensive studies on compounds having an FAAH inhibitory activity, and as a result, have found that a piperazine-1-carboxylate compound, in which benzimidazol-2-ylcarbonyl, benzofuran-2-ylcarbonyl or the like binds to the 4-position of the piperazine, has an excellent FAAH inhibitory activity and further has an action to increase the effective bladder capacity, an action to ameliorate sleep disorders, an anti-diuretic action, and an analgesic activity on lower urinary tract pain including bladder pain and the like, thereby completed the present invention. The carbamate compound of the present invention has an excellent FAAH inhibitory activity and can be used as an agent for preventing and/or treating FAAH-related diseases, particularly nocturia, interstitial cystitis, painful bladder syndrome, or chronic non-bacterial prostatitis/chronic pelvic pain syndrome.

NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS

Unsaturated nitrogen heterocyclic compounds of formula (I): (I), as defined in the specification, compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, Huntington's Disease, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts, stereoisomers or tautomers thereof which are inhibitors of the Sonic Hedgehog pathway, in particular Smo antagonists. Thus the compounds of this invention are useful for the treatment of diseases associated with abnormal hedgehog pathway activation, including cancer, for example basal cell carcinoma, medulloblastoma, prostate, pancreatic, breast, colon, bone and small cell lung cancers, and cancers of the upper GI tract.

Preparation and biological evaluation of indole, benzimidazole, and thienopyrrole piperazine carboxamides: Potent human histamine H4 antagonists

Three series of H4 receptor ligands,- derived from indoly-2-yl-(4-methyl-piperazin-1-yl)-methanones, have been synthesized and their structure-activity relationships evaluated for activity at the H 4 receptor in competitive binding and functional assays. In all cases, substitution of small lipophilic groups in the 4 and 5-positions led to increased activity in a [3H]histamine radiolabeled ligand competitive binding assay. In vitro metabolism and initial pharmacokinetic studies were performed on selected compounds leading to the identification of indole 8 and benzimidazole 40 as potent H4 antagonists with the potential for further development. In addition, both 8 and 40 demonstrated efficacy in in vitro mast cell and eosinophil chemotaxis assays.

HETEROCYCLIC COMPOUNDS

Certain thienopyrrolyl and furanopyrrolyl compounds are disclosed as useful to treat or prevent disorders and conditions mediated by the histamine H4 receptor, including allergic rhinitis.